Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

Case studies - 28 May 2019

Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France.

In the context of PRIME, a European biotechnological company entrusted BlueReg CMC team with the task of bringing the available quality data package of a synthetic peptide to global registration prerequisites for the next steps of development (the Compassionate use program in France, Phase III global program, registration in Europe and US) and to write the Quality part of the IMPD for early access submission in France.

 

Did you like this article? Share on social networks:


By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

Learn more

Discover our last white Paper

Learn more